Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

William Montgomery1 Global Health Outcomes Eli Lilly Australia Pty Ltd, West Ryde, NSW, AustraliaCorrespondence[email protected]

Tamas Treuer2 Neuroscience Research, Eli Lilly and Company, Budapest, Hungary

Wenyu Ye3 Global Statistical Sciences, Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China

Hai Bo Xue4 Medical Department, Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China

Sheng Hu Wu4 Medical Department, Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China

Li Liu4 Medical Department, Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China

Zbigniew Kadziola5 Global Statistical Sciences, Eli Lilly GmbH, Vienna, Republic of Austria

Michael D Stensland6 Agile Outcomes Research, Inc., Rochester, MN, USA

Haya Ascher-Svanum7 Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA

Your download is now in progress and you may close this window